APO Research
Talk to an analyst

APO RESEARCH · REPORT

Granulocyte-Colony Stimulating Factor (G-CSF)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026

21 December 2025219 pages

Choose your research edition.

Industry ResearchGranulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Granulocyte-Colony Stimulating Factor (G-CSF) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Granulocyte-Colony Stimulating Factor (G-CSF) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Granulocyte-Colony Stimulating Factor (G-CSF) market include Changchun GeneScience Pharmaceutical, Evive Biotech, Teva, CSPC Baike Biopharma, Shanghai Sunway Biotech, Sandoz, Amoytop Biotech, Qilu Pharmaceutical and Mylan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Granulocyte-Colony Stimulating Factor (G-CSF) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Granulocyte-Colony Stimulating Factor (G-CSF) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Granulocyte-Colony Stimulating Factor (G-CSF) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Granulocyte-Colony Stimulating Factor (G-CSF) market size, projected growth trends, production technologies, key applications, and end-use industries.

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Company

Changchun GeneScience Pharmaceutical

Evive Biotech

Teva

CSPC Baike Biopharma

Shanghai Sunway Biotech

Sandoz

Amoytop Biotech

Qilu Pharmaceutical

Mylan

Lunan Pharmaceutical

Kexing Biopharm

Jiangsu Hengrui Pharmaceuticals

Pfizer

North China Pharmaceutical

Hangzhou Jiuyuan Gene Engineering

Harbin Pharmaceutical Group

SL Pharm

Amgen

Tanvex BioPharma

Kashiv BioSciences

Italfarmaco SpA

Coherus BioSciences

Chugai Pharmaceutical

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Long-acting G-CSF

Short-acting G-CSF

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Neutropenia

Other

Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Granulocyte-Colony Stimulating Factor (G-CSF) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Granulocyte-Colony Stimulating Factor (G-CSF) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Granulocyte-Colony Stimulating Factor (G-CSF) significant trends, drivers, influence factors in global and regions.

6. To analyze Granulocyte-Colony Stimulating Factor (G-CSF) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Granulocyte-Colony Stimulating Factor (G-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Granulocyte-Colony Stimulating Factor (G-CSF) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Granulocyte-Colony Stimulating Factor (G-CSF) industry.

Chapter 3: Detailed analysis of Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Granulocyte-Colony Stimulating Factor (G-CSF) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Granulocyte-Colony Stimulating Factor (G-CSF) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends Table 2. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers Table 3. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges Table 4. Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints Table 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Company (2021-2026) Table 7. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Company (k units) & (2021-2026) Table 8. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Company (2021-2026) Table 9. Global Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/unit) of Company (2021-2026) Table 10. Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Key Company Manufacturing Base & Headquarters Table 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Company, Product Type & Application Table 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Long-acting G-CSF Table 18. Significant Companies of Short-acting G-CSF Table 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021-2026) & (k units) Table 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2027-2032) & (k units) Table 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2021-2026) Table 23. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2027-2032) Table 24. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2021-2026) Table 28. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Neutropenia Table 30. Significant Companies of Other Table 31. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021-2026) & (k units) Table 33. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2027-2032) & (k units) Table 34. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2021-2026) Table 35. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2027-2032) Table 36. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2021-2026) Table 40. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2027-2032) Table 41. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (k units) Table 43. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026) Table 44. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032) & (k units) Table 45. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2027-2032) Table 46. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Region (2021-2026) Table 49. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Region (2027-2032) Table 51. Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (k units) Table 56. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2026) Table 57. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (k units) Table 58. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2027-2032) Table 59. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Market Share by Country (2021-2026) Table 61. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Market Share by Country (2027-2032) Table 63. Changchun GeneScience Pharmaceutical Company Information Table 64. Changchun GeneScience Pharmaceutical Business Overview Table 65. Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 67. Changchun GeneScience Pharmaceutical Recent Development Table 68. Evive Biotech Company Information Table 69. Evive Biotech Business Overview Table 70. Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 72. Evive Biotech Recent Development Table 73. Teva Company Information Table 74. Teva Business Overview Table 75. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Teva Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 77. Teva Recent Development Table 78. CSPC Baike Biopharma Company Information Table 79. CSPC Baike Biopharma Business Overview Table 80. CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 82. CSPC Baike Biopharma Recent Development Table 83. Shanghai Sunway Biotech Company Information Table 84. Shanghai Sunway Biotech Business Overview Table 85. Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 87. Shanghai Sunway Biotech Recent Development Table 88. Sandoz Company Information Table 89. Sandoz Business Overview Table 90. Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 92. Sandoz Recent Development Table 93. Amoytop Biotech Company Information Table 94. Amoytop Biotech Business Overview Table 95. Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 97. Amoytop Biotech Recent Development Table 98. Qilu Pharmaceutical Company Information Table 99. Qilu Pharmaceutical Business Overview Table 100. Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 102. Qilu Pharmaceutical Recent Development Table 103. Mylan Company Information Table 104. Mylan Business Overview Table 105. Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 107. Mylan Recent Development Table 108. Lunan Pharmaceutical Company Information Table 109. Lunan Pharmaceutical Business Overview Table 110. Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 112. Lunan Pharmaceutical Recent Development Table 113. Kexing Biopharm Company Information Table 114. Kexing Biopharm Business Overview Table 115. Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 116. Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 117. Kexing Biopharm Recent Development Table 118. Jiangsu Hengrui Pharmaceuticals Company Information Table 119. Jiangsu Hengrui Pharmaceuticals Business Overview Table 120. Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 121. Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 122. Jiangsu Hengrui Pharmaceuticals Recent Development Table 123. Pfizer Company Information Table 124. Pfizer Business Overview Table 125. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 126. Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 127. Pfizer Recent Development Table 128. North China Pharmaceutical Company Information Table 129. North China Pharmaceutical Business Overview Table 130. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 131. North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 132. North China Pharmaceutical Recent Development Table 133. Hangzhou Jiuyuan Gene Engineering Company Information Table 134. Hangzhou Jiuyuan Gene Engineering Business Overview Table 135. Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 136. Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 137. Hangzhou Jiuyuan Gene Engineering Recent Development Table 138. Harbin Pharmaceutical Group Company Information Table 139. Harbin Pharmaceutical Group Business Overview Table 140. Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 141. Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 142. Harbin Pharmaceutical Group Recent Development Table 143. SL Pharm Company Information Table 144. SL Pharm Business Overview Table 145. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 146. SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 147. SL Pharm Recent Development Table 148. Amgen Company Information Table 149. Amgen Business Overview Table 150. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 151. Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 152. Amgen Recent Development Table 153. Tanvex BioPharma Company Information Table 154. Tanvex BioPharma Business Overview Table 155. Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 156. Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 157. Tanvex BioPharma Recent Development Table 158. Kashiv BioSciences Company Information Table 159. Kashiv BioSciences Business Overview Table 160. Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 161. Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 162. Kashiv BioSciences Recent Development Table 163. Italfarmaco SpA Company Information Table 164. Italfarmaco SpA Business Overview Table 165. Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 166. Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 167. Italfarmaco SpA Recent Development Table 168. Coherus BioSciences Company Information Table 169. Coherus BioSciences Business Overview Table 170. Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 171. Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 172. Coherus BioSciences Recent Development Table 173. Chugai Pharmaceutical Company Information Table 174. Chugai Pharmaceutical Business Overview Table 175. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 176. Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 177. Chugai Pharmaceutical Recent Development Table 178. Key Raw Materials Table 179. Raw Materials Key Suppliers Table 180. Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List Table 181. Granulocyte-Colony Stimulating Factor (G-CSF) Customers List Table 182. Research Programs/Design for This Report Table 183. Authors List of This Report Table 184. Secondary Sources Table 185. Primary Sources List of Figures Figure 1. Granulocyte-Colony Stimulating Factor (G-CSF) Product Image Figure 2. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032) & (k units) Figure 5. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Long-acting G-CSF Image Figure 10. Short-acting G-CSF Image Figure 11. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2021-2032) Figure 14. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2021-2032) Figure 17. Neutropenia Image Figure 18. Other Image Figure 19. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2021-2032) Figure 22. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2021-2032) Figure 25. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 30. North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 36. South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Granulocyte-Colony Stimulating Factor (G-CSF) Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Long-acting G-CSF
  • Short-acting G-CSF
Applications
  • Neutropenia
  • Other
Companies covered
  • Changchun GeneScience Pharmaceutical
  • Evive Biotech
  • Teva
  • CSPC Baike Biopharma
  • Shanghai Sunway Biotech
  • Sandoz
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • Mylan
  • Lunan Pharmaceutical
  • Kexing Biopharm
  • Jiangsu Hengrui Pharmaceuticals
  • Pfizer
  • North China Pharmaceutical
  • Hangzhou Jiuyuan Gene Engineering
  • Harbin Pharmaceutical Group
  • SL Pharm
  • Amgen
  • Tanvex BioPharma
  • Kashiv BioSciences
  • Italfarmaco SpA
  • Coherus BioSciences
  • Chugai Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  4. 1.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume (2021-2032)
  5. 1.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Granulocyte-Colony Stimulating Factor (G-CSF) Market Dynamics
  1. 2.1 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
  2. 2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
  3. 2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
  4. 2.4 Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
3 Granulocyte-Colony Stimulating Factor (G-CSF) Market by Company
  1. 3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Revenue Ranking in 2025
  2. 3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Company (2021-2026)
  3. 3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Company (2021-2026)
  4. 3.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Company (2021-2026)
  5. 3.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Ranking (2024-2026)
  6. 3.6 Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Manufacturing Base and Headquarters
  7. 3.7 Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Product Type and Application
  8. 3.8 Global Granulocyte-Colony Stimulating Factor (G-CSF) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Granulocyte-Colony Stimulating Factor (G-CSF) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Granulocyte-Colony Stimulating Factor (G-CSF) Market by Type
  1. 4.1 Granulocyte-Colony Stimulating Factor (G-CSF) Type Introduction
  2. 4.1.1 Long-acting G-CSF
  3. 4.1.2 Short-acting G-CSF
  4. 4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type
  5. 4.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type
  9. 4.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Type (2021-2032)
  11. 4.3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type (2021-2032)
5 Granulocyte-Colony Stimulating Factor (G-CSF) Market by Application
  1. 5.1 Granulocyte-Colony Stimulating Factor (G-CSF) Application Introduction
  2. 5.1.1 Neutropenia
  3. 5.1.2 Other
  4. 5.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application
  5. 5.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application
  9. 5.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Application (2021-2032)
  11. 5.3.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application (2021-2032)
6 Granulocyte-Colony Stimulating Factor (G-CSF) Regional Sales and Value Analysis
  1. 6.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2032)
  3. 6.2.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021-2026
  4. 6.2.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032)
  5. 6.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Region (2027-2032)
  9. 6.5 Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  12. 6.6.2 North America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  15. 6.7.2 Europe Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  21. 6.9.2 South America Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Country, 2025 VS 2032
7 Granulocyte-Colony Stimulating Factor (G-CSF) Country-level Sales and Value Analysis
  1. 7.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  4. 7.3.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026)
  5. 7.3.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032)
  6. 7.4 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Granulocyte-Colony Stimulating Factor (G-CSF) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun GeneScience Pharmaceutical
  2. 8.1.1 Changchun GeneScience Pharmaceutical Company Information
  3. 8.1.2 Changchun GeneScience Pharmaceutical Business Overview
  4. 8.1.3 Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Changchun GeneScience Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  6. 8.1.5 Changchun GeneScience Pharmaceutical Recent Developments
  7. 8.2 Evive Biotech
  8. 8.2.1 Evive Biotech Company Information
  9. 8.2.2 Evive Biotech Business Overview
  10. 8.2.3 Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Evive Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  12. 8.2.5 Evive Biotech Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Teva Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 CSPC Baike Biopharma
  20. 8.4.1 CSPC Baike Biopharma Company Information
  21. 8.4.2 CSPC Baike Biopharma Business Overview
  22. 8.4.3 CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 CSPC Baike Biopharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  24. 8.4.5 CSPC Baike Biopharma Recent Developments
  25. 8.5 Shanghai Sunway Biotech
  26. 8.5.1 Shanghai Sunway Biotech Company Information
  27. 8.5.2 Shanghai Sunway Biotech Business Overview
  28. 8.5.3 Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai Sunway Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  30. 8.5.5 Shanghai Sunway Biotech Recent Developments
  31. 8.6 Sandoz
  32. 8.6.1 Sandoz Company Information
  33. 8.6.2 Sandoz Business Overview
  34. 8.6.3 Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  36. 8.6.5 Sandoz Recent Developments
  37. 8.7 Amoytop Biotech
  38. 8.7.1 Amoytop Biotech Company Information
  39. 8.7.2 Amoytop Biotech Business Overview
  40. 8.7.3 Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Amoytop Biotech Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  42. 8.7.5 Amoytop Biotech Recent Developments
  43. 8.8 Qilu Pharmaceutical
  44. 8.8.1 Qilu Pharmaceutical Company Information
  45. 8.8.2 Qilu Pharmaceutical Business Overview
  46. 8.8.3 Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Qilu Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  48. 8.8.5 Qilu Pharmaceutical Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Lunan Pharmaceutical
  56. 8.10.1 Lunan Pharmaceutical Company Information
  57. 8.10.2 Lunan Pharmaceutical Business Overview
  58. 8.10.3 Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lunan Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  60. 8.10.5 Lunan Pharmaceutical Recent Developments
  61. 8.11 Kexing Biopharm
  62. 8.11.1 Kexing Biopharm Company Information
  63. 8.11.2 Kexing Biopharm Business Overview
  64. 8.11.3 Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Kexing Biopharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  66. 8.11.5 Kexing Biopharm Recent Developments
  67. 8.12 Jiangsu Hengrui Pharmaceuticals
  68. 8.12.1 Jiangsu Hengrui Pharmaceuticals Company Information
  69. 8.12.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  70. 8.12.3 Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Jiangsu Hengrui Pharmaceuticals Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  72. 8.12.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 North China Pharmaceutical
  80. 8.14.1 North China Pharmaceutical Company Information
  81. 8.14.2 North China Pharmaceutical Business Overview
  82. 8.14.3 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 North China Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  84. 8.14.5 North China Pharmaceutical Recent Developments
  85. 8.15 Hangzhou Jiuyuan Gene Engineering
  86. 8.15.1 Hangzhou Jiuyuan Gene Engineering Company Information
  87. 8.15.2 Hangzhou Jiuyuan Gene Engineering Business Overview
  88. 8.15.3 Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Hangzhou Jiuyuan Gene Engineering Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  90. 8.15.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
  91. 8.16 Harbin Pharmaceutical Group
  92. 8.16.1 Harbin Pharmaceutical Group Company Information
  93. 8.16.2 Harbin Pharmaceutical Group Business Overview
  94. 8.16.3 Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Harbin Pharmaceutical Group Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  96. 8.16.5 Harbin Pharmaceutical Group Recent Developments
  97. 8.17 SL Pharm
  98. 8.17.1 SL Pharm Company Information
  99. 8.17.2 SL Pharm Business Overview
  100. 8.17.3 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 SL Pharm Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  102. 8.17.5 SL Pharm Recent Developments
  103. 8.18 Amgen
  104. 8.18.1 Amgen Company Information
  105. 8.18.2 Amgen Business Overview
  106. 8.18.3 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Amgen Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  108. 8.18.5 Amgen Recent Developments
  109. 8.19 Tanvex BioPharma
  110. 8.19.1 Tanvex BioPharma Company Information
  111. 8.19.2 Tanvex BioPharma Business Overview
  112. 8.19.3 Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Tanvex BioPharma Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  114. 8.19.5 Tanvex BioPharma Recent Developments
  115. 8.20 Kashiv BioSciences
  116. 8.20.1 Kashiv BioSciences Company Information
  117. 8.20.2 Kashiv BioSciences Business Overview
  118. 8.20.3 Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Kashiv BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  120. 8.20.5 Kashiv BioSciences Recent Developments
  121. 8.21 Italfarmaco SpA
  122. 8.21.1 Italfarmaco SpA Company Information
  123. 8.21.2 Italfarmaco SpA Business Overview
  124. 8.21.3 Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Italfarmaco SpA Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  126. 8.21.5 Italfarmaco SpA Recent Developments
  127. 8.22 Coherus BioSciences
  128. 8.22.1 Coherus BioSciences Company Information
  129. 8.22.2 Coherus BioSciences Business Overview
  130. 8.22.3 Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Coherus BioSciences Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  132. 8.22.5 Coherus BioSciences Recent Developments
  133. 8.23 Chugai Pharmaceutical
  134. 8.23.1 Chugai Pharmaceutical Company Information
  135. 8.23.2 Chugai Pharmaceutical Business Overview
  136. 8.23.3 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Value and Gross Margin (2021-2026)
  137. 8.23.4 Chugai Pharmaceutical Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  138. 8.23.5 Chugai Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
  2. 9.1.1 Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Granulocyte-Colony Stimulating Factor (G-CSF) Sales Mode & Process
  6. 9.2 Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
  9. 9.2.3 Granulocyte-Colony Stimulating Factor (G-CSF) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst